Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04118387 · ClinicalTrials.gov registry record · Phase 4

Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment

A Phase 4 study of Sleep Disordered Breathing and Able Bodied, sponsored by VA Office of Research and Development.

Recruiting
Registry status
Phase 4
Development phase
200
Enrollment target
1
Study location

NCT04118387: Recruiting Phase 4 study of Sleep Disordered Breathing and Able Bodied, sponsored by VA Office of Research and Development.

NCT04118387 is a Phase 4 study of Sleep Disordered Breathing and Able Bodied that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 200 participants, roughly in line with the 188-participant average among 19 other Sleep Disordered Breathing trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04118387, a Phase 4 study of Sleep Disordered Breathing and Able Bodied, is actively recruiting participants, sponsored by VA Office of Research and Development.

RECRUITING
Registry status
Phase 4
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

Central sleep apnea (CSA) is common in patients with heart failure and those using opioid analgesics. Unfortunately, effective treatment of central apnea remains elusive, pressure therapy given the modest efficiency of positive airway pressure therapy. The focus of this proposal is to identify mechanistic pathways to guide future therapeutic interventions for central sleep apnea based on the strong premise that multi-modality therapy will normalize respiration and hence mitigate adverse long-term consequences of CSA. The investigators' proposed studies will test combination therapies, including positive airway pressure (PAP) plus a pharmacological agent who have heart failure or are using opioid analgesics. The investigators anticipate that findings will inform future clinical trials to improve care and quality of life among Veterans suffering from central sleep apnea, which remains difficult to treat using existing approaches.

Primary Outcome

CO2 reserve is the requisite change to induce central apnea is referred to as the CO2 reserve, which can be positive or negative.

Interventions

  • DRUG Acetazolamide + supplemental oxygen + PAP therapy
  • DRUG Zolpidem + PAP therapy
  • DRUG Buspirone + PAP therapy

Study Locations (1)

Michigan

  • John D. Dingell VA Medical Center, Detroit, MI - Detroit

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2021-01-07
Est. Completion 2026-12-31
Phase Phase 4
VA Office of Research and Development

1,668 total trials

What NCT04118387 shows while recruiting

NCT04118387 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 188-participant average among 19 other Sleep Disordered Breathing trials with a reported enrollment target.

The record links to 2 conditions, with Sleep Disordered Breathing appearing as the primary indexed condition, and to 3 interventions - of which Acetazolamide + supplemental oxygen + PAP therapy is the first listed.

NCT04118387 reports a single indexed study location in Michigan.

Frequently Asked Questions

What is clinical trial NCT04118387 about?

NCT04118387 is a clinical study titled "Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment". Central sleep apnea (CSA) is common in patients with heart failure and those using opioid analgesics. Unfortunately, effective treatment of central apnea remains elusive, pressure therapy given the modest efficiency of positive airway pressure therapy. The focus of this proposal is to identify mecha...

What is the current status of trial NCT04118387?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2021-01-07. Estimated completion is 2026-12-31.

What conditions does trial NCT04118387 study?

This clinical trial studies the following conditions: Sleep Disordered Breathing, Able Bodied.

What interventions are being tested in trial NCT04118387?

The interventions under investigation include: Acetazolamide + supplemental oxygen + PAP therapy (DRUG), Zolpidem + PAP therapy (DRUG), Buspirone + PAP therapy (DRUG).

Who is sponsoring clinical trial NCT04118387?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04118387 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sleep Disordered Breathing

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04118387's enrollment target sits among peer trials

200 4th of 19 higher than 16 of 19 other Sleep Disordered Breathing trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sleep Disordered Breathing trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04118387, the US trial registry maintained by the National Library of Medicine. NCT04118387 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.